PAX2 and breast carcinoma: Our results show that in response to estradiol, PAX2 is phosphorylated and activated in breast cancer cells of the luminal subtype selectively, via ERα; further, modulation of PAX2 expression in these cells directly impacts their invasive ability, in an ERα-dependent manner.